The clinical trial NCT01830361 assessed the utility of the multi-kinase inhibitor midostaurin as an addition to standard intensive chemotherapy in patients with newly diagnosed AML with t(8;21) and mutations in KIT and/or FLT3-ITD; 16 patients had KIT mutations (88.9%), but the study did not reach the primary endpoint of an 80% 2-yr EFS [184]. Here, FLT3 is linked to acute myeloid leukemia.